Alzheimer Disease
Conditions
Brief summary
A randomized controlled clinical study will be conducted in Xuanwu Hospital of Capital Medical University. This study initially explore the effect of selective vagus nerve(C fiber) stimulation on mild-to-moderate AD patients, in order to regulate the activity of the locus coeruleus-norepinephrine network, and to observe the improvement of cognitive function and memory function. We aim to evaluate the efficacy and safety of minimally invasive selective vagus nerve stimulation in the treatment of mild-to-moderate AD patients, to clarify the effective mechanism, and to provide an effective clinical treatment strategy.
Detailed description
This project plans to recruit 6 patients with Mild-Moderate Alzheimer's disease. They were randomly divided into vagus nerve active stimulation group and sham stimulation group, to receive vagus nerve stimulator implantation. 2 weeks after implantation, the active group will start the treatment for 12 weeks, and the stimulator of the shame group will be turned off for 12 weeks. Before treatment, cognitive assessment, head MRI and PET examination of norepinephrine distribution were completed. Side effects and adverse events were assessed at 6 weeks, 10 weeks, and 14 weeks, and cognitive assessment, head MRI and PET examination of norepinephrine distribution was also performed at the 14th week, Then, the true stimulation group continued to be turned on for 12 weeks, and the sham group turned on the stimulator to start the treatment for 12 weeks. cognitive assessment, head MRI and PET examination of norepinephrine distribution were also performed at 26 weeks.
Interventions
PROCEDUREVagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.
Sponsors
Xuanwu Hospital, Beijing
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Referring to the NIA-AA clinical AD diagnostic criteria formulated by 2011 National Institute on Aging (NIA) and Alzheimer's Disease Association (ADA) groups, select mild to moderate AD patients with positive amyloid PET; 2. Male or female AD patients between the ages of 50-85; 3. Neuropsychological evaluation reaches the following standards: MMSE 16-24 points, CDR 0.5-2 points; 4. Patients who receives a stable cholinesterase inhibitor regimen continues the oral drug with the same dose for at least 8 weeks before entering the study 5. The patient has sufficient proficiency in Mandarin Chinese and is able to complete the cognitive assessment form; 6. Those who voluntarily accept the test and sign an informed consent form.
Exclusion criteria
1. There is a clear history of cerebrovascular stroke, and there are clear symptoms or signs of neurological deficit at the time of onset, and there are corresponding responsible lesions left on neuroimaging; 2. Those with a history of alcoholism, or drug addiction, or neurological diseases that can cause cognitive impairment, such as traumatic brain injury, epilepsy, encephalitis, normal intracranial pressure hydrocephalus; 3. Suffering from systemic diseases that may lead to cognitive impairment (such as liver and kidney insufficiency, endocrine diseases, vitamin deficiency); 4. Suffering from cardiac conductive dysfunction (bradycardia) or sleep apnea syndrome; 5. Participating in other drug clinical trials; 6. There are contraindications to head MRI. 7. Those who are deemed unsuitable to participate the trial by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) | 26 weeks | To evaluate the improvement of the cognitive state of AD patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Montreal cognitive assessment(MoCA) | 26 weeks | To evaluate the improvement of the cognitive state of AD patients |
| Clinical dementia rating(CDR) | 26 weeks | To evaluate the improvement of the cognitive state of AD patients |
| World Health Organization-University of California-Los Angeles Auditory Verbal Learning Test (WHO-UCLA AVLT) | 26 weeks | To evaluate the improvement of the cognitive state of AD patients |
| Digit Span Test | 26 weeks | To evaluate the improvement of the cognitive state of AD patients |
| Trail making test(TMT) | 26 weeks | To evaluate the improvement of the cognitive state of AD patients |
| Boston naming test(BNT) | 26 weeks | To evaluate the improvement of the cognitive state of AD patients |
| Clock-drawing test | 26 weeks | To evaluate the improvement of the cognitive state of AD patients |
| Mini-mental state examination | 26 weeks | To evaluate the improvement of the cognitive state of AD patients. The scale consists of 20 questions with a total of 30 items, involving five aspects of orientation, memory, attention and calculation, recall, and language. It can be used as a screening examination and evaluation method for patients with moderate or severe dementia. |
| Modified hachinski ischemic score | 26 weeks | The modified Hachinski ischaemic scale is an attempt to differentiate Alzheimer's type dementia and multi-infarct dementia.A score of 2 or less are typical of a patient with Alzheimer's disease. A score of greater than 2 is typical of multi-infarct dementia. |
| Neuropsychiatric Inventory(NPI) | 26 weeks | To assess the improvement of common behaviors associated with dementia |
| Sturcture MRI | 26 weeks | To evaluate the morphologic change of locus coeruleus |
| Functional MRI and Diffussion Tensor Imaging | 26 weeks | To evaluate the brain connectivity change |
| Event related potential measured by electroencephalogram | 26 weeks | To evaluate the improvement of the working memory |
| The norepinephrine transporter PET(NET-PET) | 26 weeks | To evaluate the change of norepinephrine distribution of the brain |
| Global Deterioration Scale(GDS) | 26 weeks | To evaluate the improvement of the cognitive state of AD patients.The Global Deterioration Scale (GDS), developed by Dr. Barry Reisberg, provides caregivers an overview of the stages of cognitive function for those suffering from a primary degenerative dementia such as Alzheimer's disease. It is broken down into 7 different stages. Stages 1-3 are the pre-dementia stages. Stages 4-7 are the dementia stages. Biginning in stage 5, an individual can no longer survive without assistance. |
Countries
China
Contacts
Primary ContactGuoguang Zhao, M.D.
Outcome results
None listed